Ohsu Hospital And Clinics
- Type
- Teaching hospital
- Where
- PORTLAND, OR
- Medicare CCN
- 380009
- Received
- $35,157,646 in 2,716 records, 2021 ($2,149,340 general, $33,008,305 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2021 | General payment | 224 | $2,149,340 |
| 2021 | Research payment | 2,492 | $33,008,305 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 2,492 | $33,008,305 |
| Grant | 51 | $1,092,564 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 71 | $613,610 |
| Royalty or License | 15 | $275,014 |
| Consulting Fee | 6 | $106,717 |
| Space rental or facility fees (teaching hospital only) | 67 | $40,853 |
| Long term medical supply or device loan | 3 | $13,250 |
| Debt forgiveness | 11 | $7,330 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2021-12-31 | Merck Sharp & Dohme LLC | $2,088,995 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Response Assessment to Pembrolizumab in Brain Metastases from Triple Negative Breast Cancer and Melanoma, and Primary Br | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $947,830 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $300,894 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $222,283 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III Randomized, Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Ax | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $221,248 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $201,950 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine,Cisplatin versus Placebo Plus Gemcitabine,Cis | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $175,746 | Research payment | In-kind items and services | Biological, ONCOLOGY | A Phase 1 Dose-Escalation and Cohort-Expansion Study of VLS -101 in Subjects With Hematological Malignancies | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $117,264 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-blind Study of Pembrolizumab MK-3475 Plus Docetaxel Plus Prednisone versus Placebo Plus Do | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $105,442 | Research payment | Cash or cash equivalent | Biological, ONCOLOGY | A Phase 1 Dose-Escalation and Cohort-Expansion Study of VLS -101 in Subjects With Hematological Malignancies | 2021 |
| 2021-12-31 | Gilead Sciences, Inc. | $74,984 | Grant | Cash or cash equivalent | 2021 | ||
| 2021-12-31 | AstraZeneca Pharmaceuticals LP | $54,265 | Research payment | In-kind items and services | A Phase III Randomized Double-blind Placebo-controlled Multicenter Study in Adults to Determine the Safety Efficacy and | 2021 | |
| 2021-12-31 | Merck Sharp & Dohme LLC | $47,245 | Research payment | In-kind items and services | Biological, VACCINE | A Phase 3, Randomized, Double-blind, Active Comparator-controlled, Multicenter Clinical Study to Evaluate the Safety, To | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $42,977 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $42,371 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III Randomized, Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Ax | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $30,967 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $29,746 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bel | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $29,367 | Research payment | In-kind items and services | Biological, ONCOLOGY | A Phase 2, Multicenter, Clinical Study to Evaluate the Safety and Efficacy of MK-1308A Coformulated MK-1308,MK-3475 in C | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $29,270 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-blind Study of Pembrolizumab MK-3475 Plus Docetaxel Plus Prednisone versus Placebo Plus Do | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $27,046 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab MK-3475 Versus N | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $26,055 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, randomized, double blind trial of pembrolizumab MK 3475 with or without lenvatinib in participants with treat | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $25,429 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety andEfficacy of Pembrolizumab MK-3475 and Lenvatini | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $22,746 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine,Cisplatin versus Placebo Plus Gemcitabine,Cis | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $20,831 | Research payment | In-kind items and services | IMPLANON Drug, WOMENS HEALTH | A Phase 3, Open-label, Multi-center, Single Arm Study to Assess Contraceptive Efficacy and Safety of the Etonogestrel MK | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $19,548 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $19,541 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $19,541 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High Risk Stage II Melanoma A Randomized, Double-blind Ph | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $19,541 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy ,- Pembrolizumab MK-3475 as Neoadjuvant,Adj | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $16,489 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 2, Multicenter, Clinical Study to Evaluate the Safety and Efficacy of MK-1308A Coformulated MK-1308,MK-3475 in C | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $13,064 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III Study of Pembrolizumab vs Chemotherapy in Microsatellite Instability- High or Mismatched Repair Deficient Co | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $13,055 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 2 Study of Pembrolizumab MK-3475 as Monotherapy in Subjects with Advanced Hepatocellular Carcinoma KEYNOTE-224 | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $12,914 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 1,2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or P | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $12,914 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 1,2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or P | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $12,914 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 1,2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or P | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $12,755 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $11,931 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3, randomized, double blind trial of pembrolizumab MK 3475 with or without lenvatinib in participants with treat | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $10,805 | Research payment | In-kind items and services | Drug, ONCOLOGY | A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Beva | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $10,314 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $10,093 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bel | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $10,013 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $8,795 | Research payment | In-kind items and services | BRIDION Drug, NEUROSCIENCE | An assessor-blinded, randomized, controlled, single center, parallel design trial with patient masking to compare early | 2021 |
| 2021-12-31 | SERVIER PHARMACEUTICALS LLC | $7,392 | Research payment | Cash or cash equivalent | STUDY OF VORASIDENIB (AG-881) IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION (I | 2021 | |
| 2021-12-31 | Merck Sharp & Dohme LLC | $6,604 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III Randomized, Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Ax | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $6,019 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High Risk Stage II Melanoma A Randomized, Double-blind Ph | 2021 |
| 2021-12-31 | Siemens Medical Solutions USA, Inc. | $6,000 | Research payment | Cash or cash equivalent | OHSU2020MRIPR944Stevens | 2021 | |
| 2021-12-31 | Shockwave Medical, Inc | $5,000 | Long term medical supply or device loan | In-kind items and services | Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Device, Lithoplasty | 2021 | |
| 2021-12-31 | Merck Sharp & Dohme LLC | $4,228 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $3,560 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians' Choice of Single Agent Docetaxel, P | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $3,557 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III Study of Pembrolizumab vs Chemotherapy in Microsatellite Instability- High or Mismatched Repair Deficient Co | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $2,171 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 2 Study of Pembrolizumab MK-3475 as Monotherapy in Subjects with Advanced Hepatocellular Carcinoma KEYNOTE-224 | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $2,087 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Phase II Trial of Pembrolizumab MK-3475 in Subjects with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-1 | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $1,983 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase II Clinical Trial of Pembrolizumab MK-3475 in Subjects with Advanced,Unresectable or Metastatic Urothelial Cance | 2021 |
| 2021-12-31 | Adaptive Biotechnologies Corporation | $1,800 | Research payment | In-kind items and services | Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | 2021_R | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $1,778 | Research payment | In-kind items and services | LYNPARZA Biological, ONCOLOGY | A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Beva | 2021 |
| 2021-12-31 | Janssen Research & Development, LLC | $1,750 | Research payment | Cash or cash equivalent | Uptravi Selexipag the users drug registry | 2021 | |
| 2021-12-31 | Acerta Pharma LLC | $1,652 | Research payment | In-kind items and services | CALQUENCE Drug, Oncology | A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreat | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $1,645 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma | 2021 |
| 2021-12-31 | Siemens Medical Solutions USA, Inc. | $1,500 | Research payment | Cash or cash equivalent | OHSU2019MRiPR758Rooney | 2021 | |
| 2021-12-31 | Merck Sharp & Dohme LLC | $683 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 2 Proof-of-Concept Study of ACP-196 Alone and in Combination with Pembrolizumab in Subjects with Advanced or Met | 2021 |
| 2021-12-31 | Acerta Pharma LLC | $572 | Research payment | In-kind items and services | This study is a multicenter open label nonrandomized sequential group dose escalation study to assess safety tolerabilit | 2021 | |
| 2021-12-31 | AstraZeneca Pharmaceuticals LP | $456 | Research payment | In-kind items and services | CALQUENCE Drug, Oncology | A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreat | 2021 |
| 2021-12-31 | Siemens Medical Solutions USA, Inc. | $392 | Research payment | Cash or cash equivalent | OHSU2021MRIPR990Li | 2021 | |
| 2021-12-31 | Siemens Medical Solutions USA, Inc. | $375 | Research payment | Cash or cash equivalent | OHSU2018MRIPR919Kroenke | 2021 | |
| 2021-12-31 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | NOxBOX-I Device, Respiratory | 2021 | |
| 2021-12-31 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | NOxBOX-I Device, Respiratory | 2021 | |
| 2021-12-31 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | NOxBOX-I Device, Respiratory | 2021 | |
| 2021-12-31 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | NOxBOX-I Device, Respiratory | 2021 | |
| 2021-12-31 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | NOxBOX-I Device, Respiratory | 2021 | |
| 2021-12-31 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | NOxBOX-I Device, Respiratory | 2021 | |
| 2021-12-31 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | NOxBOX-I Device, Respiratory | 2021 | |
| 2021-12-31 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | NOxBOX-I Device, Respiratory | 2021 | |
| 2021-12-31 | Acerta Pharma LLC | $248 | Research payment | In-kind items and services | CALQUENCE Drug, Oncology | A Proof of Concept Study of the Combination of ACP196 and ACP319 in Subjects with Bcell Malignancies | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $46 | Research payment | In-kind items and services | JANUMET Drug, ENDOCRINOLOGY | A Phase III Multicenter, Double-Blind, Randomized Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy | 2021 |
| 2021-12-30 | Deciphera Pharmaceuticals Inc. | $89,520 | Research payment | In-kind items and services | QINLOCK Drug, ONCOLOGY | A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES | 2021 |
| 2021-12-30 | Medical Device Business Services, Inc. | $18,960 | Grant | Cash or cash equivalent | 2021 | ||
| 2021-12-29 | BeiGene, Ltd. | $9,400 | Research payment | In-kind items and services | BRUKINSA Drug, Oncology | A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chro | 2021 |
| 2021-12-29 | Genentech, Inc. | $4,047 | Research payment | Cash or cash equivalent | Drug | TENECTEPLASE IN STROKE PATIENTS BETWEEN 4 5 AND 24 HOURS | 2021 |
| 2021-12-29 | Tandem Diabetes Care, Inc. | $850 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2021 | |
| 2021-12-29 | Grifols Therapeutics LLC | $46 | Research payment | In-kind items and services | Prolastin-C Biological, Pulmonology | An Open-Label, Multicenter Study to Evaluate the Long-term Safety of Weekly Intravenous Alpha1-Proteinase Inhibitor Huma | 2021 |
| 2021-12-28 | Medicines360 | $26,110 | Research payment | Cash or cash equivalent | Liletta Device, Obstetrics/Gynecology (Women's Health) | A Phase 3 multicenter, open-label study of a Levonorgestrel 52 mg Intrauterine System for the treatment of heavy Menstru | 2021 |
| 2021-12-28 | Deciphera Pharmaceuticals Inc. | $3,015 | Research payment | Cash or cash equivalent | STUDY OF DCC-3014 IN PATIENTS WITH ADVANCED TUMORS AND TENOSYNOVIAL GIANT CELL TUMOR | 2021 | |
| 2021-12-28 | Deciphera Pharmaceuticals Inc. | $2,914 | Research payment | Cash or cash equivalent | STUDY OF DCC-3014 IN PATIENTS WITH ADVANCED TUMORS AND TENOSYNOVIAL GIANT CELL TUMOR | 2021 | |
| 2021-12-28 | Deciphera Pharmaceuticals Inc. | $2,644 | Research payment | Cash or cash equivalent | QINLOCK Drug, ONCOLOGY | INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE | 2021 |
| 2021-12-28 | Deciphera Pharmaceuticals Inc. | $2,200 | Research payment | Cash or cash equivalent | STUDY OF DCC-3014 IN PATIENTS WITH ADVANCED TUMORS AND TENOSYNOVIAL GIANT CELL TUMOR | 2021 | |
| 2021-12-28 | Deciphera Pharmaceuticals Inc. | $2,000 | Research payment | Cash or cash equivalent | STUDY OF DCC-3014 IN PATIENTS WITH ADVANCED TUMORS AND TENOSYNOVIAL GIANT CELL TUMOR | 2021 | |
| 2021-12-28 | Deciphera Pharmaceuticals Inc. | $1,759 | Research payment | Cash or cash equivalent | QINLOCK Drug, ONCOLOGY | INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE | 2021 |
| 2021-12-28 | Deciphera Pharmaceuticals Inc. | $1,329 | Research payment | Cash or cash equivalent | QINLOCK Drug, ONCOLOGY | INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE | 2021 |
| 2021-12-28 | Deciphera Pharmaceuticals Inc. | $500 | Research payment | Cash or cash equivalent | STUDY OF DCC-3014 IN PATIENTS WITH ADVANCED TUMORS AND TENOSYNOVIAL GIANT CELL TUMOR | 2021 | |
| 2021-12-28 | Deciphera Pharmaceuticals Inc. | $375 | Research payment | Cash or cash equivalent | STUDY OF DCC-3014 IN PATIENTS WITH ADVANCED TUMORS AND TENOSYNOVIAL GIANT CELL TUMOR | 2021 | |
| 2021-12-28 | Deciphera Pharmaceuticals Inc. | $318 | Research payment | Cash or cash equivalent | QINLOCK Drug, ONCOLOGY | INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE | 2021 |
| 2021-12-28 | Deciphera Pharmaceuticals Inc. | $268 | Research payment | Cash or cash equivalent | STUDY OF DCC-3014 IN PATIENTS WITH ADVANCED TUMORS AND TENOSYNOVIAL GIANT CELL TUMOR | 2021 | |
| 2021-12-28 | Deciphera Pharmaceuticals Inc. | $268 | Research payment | Cash or cash equivalent | STUDY OF DCC-3014 IN PATIENTS WITH ADVANCED TUMORS AND TENOSYNOVIAL GIANT CELL TUMOR | 2021 | |
| 2021-12-28 | Deciphera Pharmaceuticals Inc. | $268 | Research payment | Cash or cash equivalent | STUDY OF DCC-3014 IN PATIENTS WITH ADVANCED TUMORS AND TENOSYNOVIAL GIANT CELL TUMOR | 2021 | |
| 2021-12-28 | Deciphera Pharmaceuticals Inc. | $268 | Research payment | Cash or cash equivalent | STUDY OF DCC-3014 IN PATIENTS WITH ADVANCED TUMORS AND TENOSYNOVIAL GIANT CELL TUMOR | 2021 | |
| 2021-12-28 | Deciphera Pharmaceuticals Inc. | $268 | Research payment | Cash or cash equivalent | STUDY OF DCC-3014 IN PATIENTS WITH ADVANCED TUMORS AND TENOSYNOVIAL GIANT CELL TUMOR | 2021 | |
| 2021-12-28 | Deciphera Pharmaceuticals Inc. | $268 | Research payment | Cash or cash equivalent | STUDY OF DCC-3014 IN PATIENTS WITH ADVANCED TUMORS AND TENOSYNOVIAL GIANT CELL TUMOR | 2021 | |
| 2021-12-27 | Incyte Corporation | $23,456 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2021 | |
| 2021-12-27 | Blueprint Medicines Corporation | $3,845 | Research payment | Cash or cash equivalent | Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Patients With Thyroid Cancer, Non-Small | 2021 | |
| 2021-12-27 | W. L. Gore & Associates, Inc. | $1,500 | Research payment | Cash or cash equivalent | Product in Development Device, Devices | GREAT Global Registry for Endovascular Aortic Treatment | 2021 |
| 2021-12-25 | Deciphera Pharmaceuticals Inc. | $10,000 | Research payment | Cash or cash equivalent | QINLOCK Drug, ONCOLOGY | A DRUG-DRUG INTERACTION STUDY TO EVALUATE THE EFFECT OF RIPRETINIB ON THE PHARMACOKINETICS OF A CYP2C8 PROBE SUBSTRATE I | 2021 |
| 2021-12-25 | Deciphera Pharmaceuticals Inc. | $8,000 | Research payment | Cash or cash equivalent | QINLOCK Drug, ONCOLOGY | A DRUG-DRUG INTERACTION STUDY TO EVALUATE THE EFFECT OF RIPRETINIB ON THE PHARMACOKINETICS OF A CYP2C8 PROBE SUBSTRATE I | 2021 |
| 2021-12-25 | Deciphera Pharmaceuticals Inc. | $3,082 | Research payment | Cash or cash equivalent | QINLOCK Drug, ONCOLOGY | A DRUG-DRUG INTERACTION STUDY TO EVALUATE THE EFFECT OF RIPRETINIB ON THE PHARMACOKINETICS OF A CYP2C8 PROBE SUBSTRATE I | 2021 |
| 2021-12-25 | Deciphera Pharmaceuticals Inc. | $3,000 | Research payment | Cash or cash equivalent | QINLOCK Drug, ONCOLOGY | A DRUG-DRUG INTERACTION STUDY TO EVALUATE THE EFFECT OF RIPRETINIB ON THE PHARMACOKINETICS OF A CYP2C8 PROBE SUBSTRATE I | 2021 |
| 2021-12-25 | Deciphera Pharmaceuticals Inc. | $2,680 | Research payment | Cash or cash equivalent | QINLOCK Drug, ONCOLOGY | A DRUG-DRUG INTERACTION STUDY TO EVALUATE THE EFFECT OF RIPRETINIB ON THE PHARMACOKINETICS OF A CYP2C8 PROBE SUBSTRATE I | 2021 |
| 2021-12-25 | Deciphera Pharmaceuticals Inc. | $1,072 | Research payment | Cash or cash equivalent | QINLOCK Drug, ONCOLOGY | A DRUG-DRUG INTERACTION STUDY TO EVALUATE THE EFFECT OF RIPRETINIB ON THE PHARMACOKINETICS OF A CYP2C8 PROBE SUBSTRATE I | 2021 |
| 2021-12-25 | Deciphera Pharmaceuticals Inc. | $1,000 | Research payment | Cash or cash equivalent | QINLOCK Drug, ONCOLOGY | A DRUG-DRUG INTERACTION STUDY TO EVALUATE THE EFFECT OF RIPRETINIB ON THE PHARMACOKINETICS OF A CYP2C8 PROBE SUBSTRATE I | 2021 |
| 2021-12-24 | Janssen Research & Development, LLC | $25,199 | Research payment | Cash or cash equivalent | TREMFYA Drug, Immunology | An open label pilot trial of guselkumab in the treatment of adults with pityriasis rubra pilaris PRP | 2021 |
| 2021-12-24 | Janssen Research & Development, LLC | $18,266 | Research payment | Cash or cash equivalent | A Phase 3 Randomized Multi Center Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High risk | 2021 | |
| 2021-12-24 | Epizyme, Inc. | $2,500 | Research payment | Cash or cash equivalent | TAZVERIK Drug, ONCOLOGY | A PHASE1B/3 GLOBAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF TAZEMETOSTAT IN COMBINATION WITH DOXORUBICIN A | 2021 |
| 2021-12-24 | Janssen Research & Development, LLC | $2,384 | Research payment | Cash or cash equivalent | A Phase 3 Randomized Multi Center Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High risk | 2021 | |
| 2021-12-23 | Alnylam Pharmaceuticals Inc. | $10,950 | Research payment | Cash or cash equivalent | HELIOS-A: A Phase 3 Global, Randomized, Open-label Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients | 2021 | |
| 2021-12-23 | SERVIER PHARMACEUTICALS LLC | $2,217 | Research payment | Cash or cash equivalent | STUDY OF VORASIDENIB (AG-881) IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION (I | 2021 | |
| 2021-12-22 | SEAGEN INC. | $39,800 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2021 |
| 2021-12-22 | Amgen Inc. | $25,218 | Research payment | Cash or cash equivalent | LUMAKRAS Drug, Oncology | AMG 510 - Adv. KRAS G12C solid tumors_20190135 | 2021 |
| 2021-12-22 | Gilead Sciences, Inc. | $21,036 | Research payment | Cash or cash equivalent | A Phase 1b Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of GS | 2021 | |
| 2021-12-22 | Gilead Sciences, Inc. | $6,458 | Research payment | Cash or cash equivalent | A Phase 1b Dose Escalation and Dose Expansion Study of ONO/GS-4059 in Combination with other Targeted Anti-cancer Therap | 2021 | |
| 2021-12-22 | Zogenix Inc. | $5,158 | Research payment | Cash or cash equivalent | Fintepla Drug, Treatment of seizures | LGS Efficacy & Safety | 2021 |
| 2021-12-22 | Novo Nordisk AS | $5,022 | Research payment | Cash or cash equivalent | Drug, Diabetes | EX9536-4388 | 2021 |
| 2021-12-22 | Medicines360 | $3,847 | Research payment | Cash or cash equivalent | Liletta Device, Obstetrics/Gynecology (Women's Health) | A Phase 3 multicenter, open-label study of a Levonorgestrel 52 mg Intrauterine System for the treatment of heavy Menstru | 2021 |
| 2021-12-22 | MACROGENICS, INC. | $3,335 | Research payment | Cash or cash equivalent | MARGENZA Drug, Oncology | COMBINATION MARGETUXIMAB, INCMGA00012, MGD013, AND CHEMOTHERAPY PHASE 2 3 TRIAL IN HER2 GASTRIC GEJ CANCER MAHOGANY | 2021 |
| 2021-12-22 | Medicines360 | $1,506 | Research payment | Cash or cash equivalent | Liletta Device, Obstetrics/Gynecology (Women's Health) | A Phase 3 multicenter, open-label study of a Levonorgestrel 52 mg Intrauterine System for the treatment of heavy Menstru | 2021 |
| 2021-12-22 | SEAGEN INC. | $324 | Research payment | Cash or cash equivalent | A Study of SGN-CD228A in Advanced Solid Tumors | 2021 | |
| 2021-12-21 | Incyte Corporation | $53,411 | Research payment | Cash or cash equivalent | A Multicenter, Phase 1, open-label study of the FGFR inhibitor pemigatinib (INCB054828) administered after chemotherapy | 2021 | |
| 2021-12-21 | Novartis Pharma AG | $50,000 | Royalty or License | Cash or cash equivalent | GLEEVEC Drug, ONCOLOGY | 2021 | |
| 2021-12-21 | Janssen Research & Development, LLC | $3,701 | Research payment | Cash or cash equivalent | A Phase 3 Randomized Multi Center Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High risk | 2021 | |
| 2021-12-21 | Incyte Corporation | $2,353 | Research payment | Cash or cash equivalent | Phase I Study to Evaluate Safety of Ruxolitinib in Combination with Venetoclax in Patients with Relapsed/Refractory Acut | 2021 | |
| 2021-12-20 | Gilead Sciences, Inc. | $23,072 | Research payment | Cash or cash equivalent | A Phase 2 multi-arm study of magrolimab in patients with solid tumors | 2021 | |
| 2021-12-20 | Exelixis Inc. | $7,291 | Research payment | Cash or cash equivalent | CABOMETYX Drug, Oncology | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | 2021 |
| 2021-12-20 | United Therapeutics Corporation | $6,800 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE | 2021 | |
| 2021-12-20 | United Therapeutics Corporation | $6,152 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE | 2021 | |
| 2021-12-20 | Janssen Research & Development, LLC | $5,585 | Research payment | Cash or cash equivalent | A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly D | 2021 | |
| 2021-12-20 | Janssen Research & Development, LLC | $2,945 | Research payment | Cash or cash equivalent | A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly D | 2021 | |
| 2021-12-20 | United Therapeutics Corporation | $2,656 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE | 2021 | |
| 2021-12-20 | United Therapeutics Corporation | $2,598 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE | 2021 | |
| 2021-12-20 | United Therapeutics Corporation | $2,520 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE | 2021 | |
| 2021-12-20 | GENZYME CORPORATION | $2,375 | Research payment | Cash or cash equivalent | Fabry LSD Data Registry | 2021 | |
| 2021-12-20 | GENZYME CORPORATION | $2,170 | Research payment | Cash or cash equivalent | A Phase 3 Randomized, Multicenter, Multinational, Double-blinded Study Comparing the Efficacy and Safety of Repeated Biw | 2021 | |
| 2021-12-20 | United Therapeutics Corporation | $1,773 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE | 2021 | |
| 2021-12-20 | United Therapeutics Corporation | $1,209 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE | 2021 | |
| 2021-12-20 | United Therapeutics Corporation | $400 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE | 2021 | |
| 2021-12-20 | GENZYME CORPORATION | $350 | Research payment | Cash or cash equivalent | MPS-I LSD Data Registry | 2021 | |
| 2021-12-17 | Organon Llc | $12,952 | Research payment | Cash or cash equivalent | IMPLANON Drug, CONTRACEPTIVES | A Phase 3, Open-label, Multi-center, Single Arm Study to Assess Contraceptive Efficacy and Safety of the Etonogestrel MK | 2021 |
| 2021-12-17 | E.R. Squibb & Sons, L.L.C. | $6,600 | Research payment | Cash or cash equivalent | Phase I Combo w Elotuzumab | 2021 | |
| 2021-12-17 | Genentech, Inc. | $6,000 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | B FAST BLOOD FIRST ASSAY SCREENING TRIAL UMBRELLA STUDY BFAST BLOOD FIRST ASSAY SCREENING TRIAL | 2021 |
| 2021-12-17 | United Therapeutics Corporation | $5,637 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE | 2021 | |
| 2021-12-17 | Ipsen Bioscience Inc. | $5,014 | Research payment | Cash or cash equivalent | ONIVYDE Drug, Oncology | An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Le | 2021 |
| 2021-12-17 | UPSHER-SMITH LABORATORIES LLC | $3,796 | Research payment | Cash or cash equivalent | TOPIRAMATE Drug, NEUROLOGY | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 4 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF QUD | 2021 |
| 2021-12-17 | Genentech, Inc. | $3,636 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | B FAST BLOOD FIRST ASSAY SCREENING TRIAL UMBRELLA STUDY BFAST BLOOD FIRST ASSAY SCREENING TRIAL | 2021 |
| 2021-12-17 | Aesculap Biologics, LLC | $2,200 | Research payment | Cash or cash equivalent | NOVOCART 3D Device, CARTILAGE REPAIR AND REGENERATION | NOVOCART 3D FOR THE TREATMENT OF ARTICULAR CARTILAGE OF THE KNEE (N3D) | 2021 |
| 2021-12-17 | UPSHER-SMITH LABORATORIES LLC | $1,596 | Research payment | Cash or cash equivalent | TOPIRAMATE Drug, NEUROLOGY | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 4 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF QUD | 2021 |
| 2021-12-17 | W. L. Gore & Associates, Inc. | $809 | Research payment | Cash or cash equivalent | Product in Development Device, Devices | Evaluation of the GORE TAG TSSB LSA Endoprosthesis in the Treatment of Proximal Descending Thoracic Aortic Aneurysms | 2021 |
| 2021-12-17 | Janssen Research & Development, LLC | $750 | Research payment | Cash or cash equivalent | A Phase 3 Randomized Multi Center Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High risk | 2021 | |
| 2021-12-17 | Deciphera Pharmaceuticals Inc. | $500 | Research payment | Cash or cash equivalent | QINLOCK Drug, ONCOLOGY | INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE | 2021 |
| 2021-12-17 | Deciphera Pharmaceuticals Inc. | $415 | Research payment | Cash or cash equivalent | QINLOCK Drug, ONCOLOGY | INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE | 2021 |
| 2021-12-17 | Deciphera Pharmaceuticals Inc. | $268 | Research payment | Cash or cash equivalent | QINLOCK Drug, ONCOLOGY | INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE | 2021 |
| 2021-12-17 | Deciphera Pharmaceuticals Inc. | $268 | Research payment | Cash or cash equivalent | QINLOCK Drug, ONCOLOGY | INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE | 2021 |
| 2021-12-17 | Deciphera Pharmaceuticals Inc. | $268 | Research payment | Cash or cash equivalent | QINLOCK Drug, ONCOLOGY | INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE | 2021 |
| 2021-12-17 | Deciphera Pharmaceuticals Inc. | $268 | Research payment | Cash or cash equivalent | QINLOCK Drug, ONCOLOGY | INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE | 2021 |
| 2021-12-17 | Deciphera Pharmaceuticals Inc. | $268 | Research payment | Cash or cash equivalent | QINLOCK Drug, ONCOLOGY | INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE | 2021 |
| 2021-12-16 | Otsuka Pharmaceutical Co., Ltd. | $19,056 | Research payment | Cash or cash equivalent | PHASE 1-2 STUDY OF THE SAFETY, PHARMACOKINETICS, AND PRELIMINARY ACTIVITY OF ASTX660 IN SUBJECTS WITH ADVANCED SOLID TUM | 2021 | |
| 2021-12-16 | SEAGEN INC. | $9,761 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer | 2021 |
| 2021-12-16 | Mallinckrodt Hospital Products Inc. | $3,400 | Research payment | Cash or cash equivalent | AN OPEN LABEL EXPANDED ACCESS TREATMENT PROTOCOL FOR VTS-270 (2-HYDROXYPROPYL-CYCLODEXTRIN) IN PATIENTS WITH NEUROLOGIC | 2021 | |
| 2021-12-16 | SEAGEN INC. | $3,238 | Research payment | Cash or cash equivalent | A Study of SGN-CD228A in Advanced Solid Tumors | 2021 | |
| 2021-12-16 | Pharmacyclics LLC, an AbbVie Company | $1,554 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | 2021 | |
| 2021-12-16 | Pharmacyclics LLC, an AbbVie Company | $1,554 | Grant | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | 2021 | |
| 2021-12-16 | Janssen Research & Development, LLC | $1,205 | Research payment | Cash or cash equivalent | A Randomized Double-blind Placebo controlled Phase 3 Study of the Bruton's Tyrosine Kinase BTK Inhibitor PCI32765 Ibruti | 2021 | |
| 2021-12-16 | Regeneron Pharmaceuticals, Inc. | $1,000 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A PROSPECTIVE OBSERVATIONAL STUDY OF ADULT PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2021 |
| 2021-12-16 | Regeneron Pharmaceuticals, Inc. | $1,000 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A PROSPECTIVE OBSERVATIONAL STUDY OF ADULT PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2021 |
| 2021-12-16 | Janssen Research & Development, LLC | $1,000 | Research payment | Cash or cash equivalent | A Randomized Double-blind Placebo controlled Phase 3 Study of the Bruton's Tyrosine Kinase BTK Inhibitor PCI32765 Ibruti | 2021 | |
| 2021-12-16 | SEAGEN INC. | $704 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2021 |
| 2021-12-16 | Janssen Research & Development, LLC | $552 | Research payment | Cash or cash equivalent | A Phase 3 Randomized Multi Center Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High risk | 2021 | |
| 2021-12-16 | Janssen Research & Development, LLC | $384 | Research payment | Cash or cash equivalent | Phase 2 Randomized Open Label Study Comparing Daratumumab Lenalidomide Bortezomib and Dexamethasone DRVd Versus Lenalido | 2021 | |
| 2021-12-16 | Deciphera Pharmaceuticals Inc. | $153 | Research payment | Cash or cash equivalent | QINLOCK Drug, ONCOLOGY | INVICTUS A PHASE 3 INTERVENTIONAL DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF DCC-2618 IN | 2021 |
| 2021-12-16 | Deciphera Pharmaceuticals Inc. | $153 | Research payment | Cash or cash equivalent | QINLOCK Drug, ONCOLOGY | INVICTUS A PHASE 3 INTERVENTIONAL DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF DCC-2618 IN | 2021 |
| 2021-12-16 | Deciphera Pharmaceuticals Inc. | $153 | Research payment | Cash or cash equivalent | QINLOCK Drug, ONCOLOGY | INVICTUS A PHASE 3 INTERVENTIONAL DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF DCC-2618 IN | 2021 |
| 2021-12-16 | Deciphera Pharmaceuticals Inc. | $153 | Research payment | Cash or cash equivalent | QINLOCK Drug, ONCOLOGY | INVICTUS A PHASE 3 INTERVENTIONAL DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF DCC-2618 IN | 2021 |
| 2021-12-16 | Deciphera Pharmaceuticals Inc. | $153 | Research payment | Cash or cash equivalent | QINLOCK Drug, ONCOLOGY | INVICTUS A PHASE 3 INTERVENTIONAL DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF DCC-2618 IN | 2021 |
| 2021-12-15 | Deciphera Pharmaceuticals Inc. | $55,950 | Research payment | In-kind items and services | QINLOCK Drug, ONCOLOGY | INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE | 2021 |
| 2021-12-15 | ABBVIE INC. | $23,320 | Research payment | Cash or cash equivalent | HUMIRA Biological, IMMUNOLOGY | A 10-Year, Post-marketing, Observational Study to Assess Long Term Safety of HUMIRA (Adalimumab) in Adult Patients with | 2021 |
| 2021-12-15 | ABBVIE INC. | $16,888 | Research payment | Cash or cash equivalent | An Extension Study of ABBV-8E12 in Early Alzheimers Disease | 2021 | |
| 2021-12-15 | Zimmer Biomet Holdings, Inc. | $4,000 | Grant | Cash or cash equivalent | Grants Device, General | 2021 | |
| 2021-12-15 | Genentech, Inc. | $3,915 | Research payment | Cash or cash equivalent | Drug | PORT DELIVERY SYSTEM OF RANIBIZUMAB EXTENSION STUDY | 2021 |
| 2021-12-15 | Kaneka Medical America LLC | $2,818 | Consulting Fee (12 payments) | Cash or cash equivalent | LIPOSORBER Device, Lipid Apheresis | 2021 | |
| 2021-12-15 | Gilead Sciences, Inc. | $2,103 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Multicenter Study Comparing Magrolimab in Combination with Azacitidine versus Azacitidine Pl | 2021 | |
| 2021-12-15 | Genentech USA, Inc. | $1,554 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Activase Biological, Metabolism & Primary Care | 2021 | |
| 2021-12-15 | Zimmer Biomet Holdings, Inc. | $1,320 | Research payment | Cash or cash equivalent | G7 Device, Hips | G7 Dual Mobility PMCF | 2021 |
| 2021-12-15 | Deciphera Pharmaceuticals Inc. | $850 | Research payment | Cash or cash equivalent | QINLOCK Drug, ONCOLOGY | A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES | 2021 |
| 2021-12-15 | Tandem Diabetes Care, Inc. | $650 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2021 | |
| 2021-12-15 | Ortho-Clinical Diagnostics, Inc. | $550 | Research payment | Cash or cash equivalent | VITROS 3600 Immunodiagnostic System Device, Diagnostics | hs Troponin I | 2021 |
| 2021-12-15 | Deciphera Pharmaceuticals Inc. | $500 | Research payment | Cash or cash equivalent | QINLOCK Drug, ONCOLOGY | A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES | 2021 |
| 2021-12-15 | Eli Lilly and Company | $233 | Research payment | In-kind items and services | A PHASE 3, 12 MONTH, OPEN LABEL STUDY OF LASMIDITAN IN PEDIATRIC PATIENTS WITH MIGRAINE PIONEER PEDS2 | 2021 | |
| 2021-12-15 | Deciphera Pharmaceuticals Inc. | $153 | Research payment | Cash or cash equivalent | QINLOCK Drug, ONCOLOGY | A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES | 2021 |
| 2021-12-15 | Deciphera Pharmaceuticals Inc. | $153 | Research payment | Cash or cash equivalent | QINLOCK Drug, ONCOLOGY | A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES | 2021 |
| 2021-12-15 | Deciphera Pharmaceuticals Inc. | $153 | Research payment | Cash or cash equivalent | QINLOCK Drug, ONCOLOGY | A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES | 2021 |
| 2021-12-15 | Deciphera Pharmaceuticals Inc. | $153 | Research payment | Cash or cash equivalent | QINLOCK Drug, ONCOLOGY | A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES | 2021 |
| 2021-12-15 | Deciphera Pharmaceuticals Inc. | $153 | Research payment | Cash or cash equivalent | QINLOCK Drug, ONCOLOGY | A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES | 2021 |
| 2021-12-15 | Eli Lilly and Company | $135 | Research payment | In-kind items and services | PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREA | 2021 | |
| 2021-12-14 | Akcea Therapeutics, Inc. | $62,735 | Research payment | Cash or cash equivalent | TEGSEDI Drug, NEUROLOGY | IST-2019-1101 - Machine Learning for identification of wild-type and hereditary ATTR Amyloidosis | 2021 |
| 2021-12-14 | Dexcom, Inc. | $23,411 | Research payment | Cash or cash equivalent | DEXCOM G6 TRANSMITTER Device, ENDOCRINOLOGY | PREDIABETES AND TYPE 2 DIABETES DATA COLLECTION STUDY: T2 HELP (OBSERVATIONAL STUDY) | 2021 |
| 2021-12-14 | Medtronic, Inc. | $21,266 | Research payment | Cash or cash equivalent | Micra Device, Pacemakers | AccelAV Study | 2021 |
| 2021-12-14 | Pharmacyclics LLC, an AbbVie Company | $4,296 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD | 2021 |
The latest 200 records of 2,716.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Portland, OR, county Multnomah County, OR, state Oregon; placed by its city name.
| Measure | Place (city or town) Portland, OR | County Multnomah County, OR | State Oregon |
|---|---|---|---|
| Population B01003 | 641,165 | 801,477 | 4,254,293 |
| Population, 2020 census P1 | 652,503 | 815,428 | 4,237,256 |
| Median age B01002 | 38.8 | 38.7 | 40.4 |
| Under 18 B01001 | 16.3% | 17.6% | 19.9% |
| 65 and over B01001 | 14.5% | 14.8% | 19.1% |
| Households B11001 | 289,705 | 349,803 | 1,718,422 |
| Foreign born B05002 | 12.4% | 13.0% | 9.8% |
| Median household income B19013 | $90,919 | $88,766 | $83,011 |
| Median family income B19113 | $124,706 | $118,358 | $102,281 |
| Per capita income B19301 | $57,029 | $53,996 | $45,612 |
| Poverty rate B17001 | 12.7% | 12.6% | 11.9% |
| Unemployment rate B23025 | 5.8% | 5.7% | 5.4% |
| Civilian labor force B23025 | 387,826 | 471,313 | 2,183,462 |
| Mean commute (minutes) B08013 | 24.1 | 24.4 | 23.0 |
| Bachelor's degree or higher B15003 | 53.8% | 48.9% | 36.8% |
| Housing units B25001 | 307,719 | 371,179 | 1,857,992 |
| Owner-occupied B25003 | 52.0% | 53.4% | 63.3% |
| Renters B25003 | 48.0% | 46.6% | 36.7% |
| Median home value B25077 | $581,500 | $552,700 | $477,600 |
| Median gross rent B25064 | $1,655 | $1,646 | $1,525 |
| White, not Hispanic B03002 | 65.8% | 65.2% | 71.4% |
| Black B03002 | 5.5% | 5.3% | 1.8% |
| Hispanic or Latino B03002 | 12.0% | 13.5% | 14.7% |
| Asian B03002 | 8.0% | 7.4% | 4.4% |
| American Indian and Alaska Native B03002 | 0.4% | 0.4% | 0.6% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Portland, OR.
Comments